Tyra Biosciences Inc. (NASDAQ:TYRA) presented phase I/II data for its FGFR3 inhibitor, TYRA-300, in metastatic urothelial cancer from the ongoing Surf301 trial. Despite the positive outcome, the company's shares closed down 23% on October 25, at $21.93.
Surf301 Trial Results
The Surf301 phase I/II study is evaluating TYRA-300 in patients with metastatic urothelial cancer. Preliminary data suggests promising activity of the drug. Tyler Van Buren, an analyst at TD Cowen, described the results as "fantastic," underscoring the potential clinical significance of TYRA-300 in this patient population.
TYRA-300: A Selective FGFR3 Inhibitor
TYRA-300 is a small molecule designed to selectively inhibit FGFR3, a receptor tyrosine kinase that plays a role in cell growth and differentiation. Aberrant FGFR3 signaling is implicated in the development and progression of urothelial cancer, making it a rational therapeutic target. The drug is designed to overcome resistance mechanisms that limit the effectiveness of existing FGFR inhibitors.
Urothelial Cancer Treatment Landscape
Urothelial cancer, primarily bladder cancer, represents a significant unmet medical need. While platinum-based chemotherapy remains a standard first-line treatment, many patients progress, highlighting the need for novel therapies. FGFR inhibitors have emerged as a targeted treatment option for patients with specific FGFR3 alterations. TYRA-300's data offers hope for patients with urothelial cancer.
